EP4719402A1 — Sparsentan for use in a method of treating iga-mediated diseases
Assigned to Travere Therapeutics Inc · Expires 2026-04-08 · 0y expired
What this patent protects
Methods of preventing or treating immunoglobulin A-mediated diseases, such as immunoglobulin A nephropathy, by treatment with sparsentan, or a pharmaceutically acceptable salt thereof, are provided.
USPTO Abstract
Methods of preventing or treating immunoglobulin A-mediated diseases, such as immunoglobulin A nephropathy, by treatment with sparsentan, or a pharmaceutically acceptable salt thereof, are provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.